Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2023-11-02 00:00:00 ET · period of report 2023-11-01 · accession 0000950170-23-058314 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-02 | 2023-11-01 | TNGX | Crystal Adam | See Remarks | S - Sale | $8.39 | -7,507 | 81.2K | -8% | -$63.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-01 | S | D | 7,507 | $8.39 | 81,250 | D | — | — | (F1) Includes 7,507 shares that were acquired on October 31, 2023 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |